Categories LATEST

Biogen’s quarterly profit jumps but stock falls

American biotech firm Biogen (BIIB), whose shares fell nearly 16.5% this year, saw it further dip 2.4% to $259.30 in pre-market trade, despite the strong first-quarter earnings.

Earnings, excluding items, jumped to $6.05 per share this quarter from last year’s $5.20 per share. On a diluted basis, Biogen reported earnings of $5.54 per share, marking a modest improvement from $3.46 per share during the same quarter last year.

Weeks back, Biogen along with its South Korean partner Samsung Bioepis put an end to the long-running fight with AbbVie, over the biosimilar version of the latter’s key drug Humira. Based on the new deal, the partners will sell the copy-cat version of Humira — Imraldi — in Europe. This is expected to strengthen the firm’s biosimilar portfolio and even drive the revenue growth.

Revenue during the quarter jumped 11% to $3.1 billion, propelled by SPINRAZA (to treat spinal muscular atrophy), which contributed $364 million in global revenues, and biosimilars that contributed $128 million.

The company, with its wide range of products, leads the multiple-sclerosis market. During the quarter, Tecfidera — the top-selling multiple-sclerosis drug — generated revenues of about $987 million during the quarter. But since this space is getting crowded at a faster pace, the biotech firm is diversifying its portfolio.

The company is focusing on building its neuroscience pipeline. Hence, it paid $1 billion to expand its partnership with Ionis Pharma (IONS) to develop new antisense drugs to treat a wide of neurological disorders. During the quarter, the company even completed the transaction — of approx. $600 million — to acquire an experimental drug from pharma giant Pfizer that is developed to treat Schizophrenia.

“As pioneers in neuroscience, we continued to advance and expand our portfolio of potential breakthrough treatments for areas of high unmet need. We have added a new Phase 2 asset in our emerging growth area of neuropsychiatry, and we meaningfully enhanced our collaboration with Ionis to develop a new pipeline of gene- based therapies for neurological diseases,” said Michel Vounatsos, Biogen’s Chief Executive Officer.

Biogen Q1 2018 Earnings

Most Popular

Should investors worry about Micron’s (MU) weak Q4 results and guidance?

The semiconductor industry is a rapidly growing business segment that currently thrives on the digital transformation wave. The demand for memory chips and other semiconductor products increased over the years,

What has Bed Bath & Beyond (BBBY) outlined for this fiscal year?

Shares of Bed Bath & Beyond (NASDAQ: BBBY) were up on Friday, a day after the company delivered disappointing results for the second quarter of 2022. The company reported a

NKE Earnings: Highlights of Nike’s Q1 2023 results

Nike, Inc. (NYSE: NKE) has reported a decrease in net profit for the first quarter of 2023, despite a modest increase in revenues. The company's stock suffered a big loss

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top